Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1958 1
1959 1
1962 1
1963 1
1966 1
1970 1
1973 2
1975 2
1978 3
1979 1
1981 2
1982 1
1983 2
1984 3
1985 10
1986 10
1987 12
1988 12
1989 17
1990 8
1991 15
1992 16
1993 12
1994 19
1995 23
1996 31
1997 41
1998 49
1999 58
2000 82
2001 92
2002 112
2003 169
2004 171
2005 234
2006 315
2007 332
2008 367
2009 431
2010 499
2011 541
2012 619
2013 734
2014 689
2015 814
2016 766
2017 780
2018 802
2019 869
2020 912
2021 937
2022 892
2023 398

Text availability

Article attribute

Article type

Publication date

Search Results

11,356 results

Results by year

Filters applied: . Clear all
Page 1
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.
Dubrot J, Du PP, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, Freeman SS, Allen PM, Olander KE, Ockerman KM, Wolfe CH, Wiesmann F, Knudsen NH, Tsao HW, Iracheta-Vellve A, Schneider EM, Rivera-Rosario AN, Kohnle IC, Pope HW, Ayer A, Mishra G, Zimmer MD, Kim SY, Mahapatra A, Ebrahimi-Nik H, Frederick DT, Boland GM, Haining WN, Root DE, Doench JG, Hacohen N, Yates KB, Manguso RT. Dubrot J, et al. Among authors: kim sy. Nat Immunol. 2022 Oct;23(10):1495-1506. doi: 10.1038/s41590-022-01315-x. Epub 2022 Sep 23. Nat Immunol. 2022. PMID: 36151395
Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.
Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Negrao MV, et al. Among authors: kim sy. Cancer Discov. 2023 Apr 17:CD-22-1420. doi: 10.1158/2159-8290.CD-22-1420. Online ahead of print. Cancer Discov. 2023. PMID: 37068173
Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial.
Sung KC, Sung JH, Cho EJ, Ahn JC, Han SH, Kim W, Kim KH, Sohn IS, Shin J, Kim SY, Kim KI, Kang SM, Park SJ, Kim YJ, Shin JH, Park SM, Park CG. Sung KC, et al. Among authors: kim sy. J Clin Hypertens (Greenwich). 2022 Oct;24(10):1298-1309. doi: 10.1111/jch.14570. Epub 2022 Sep 12. J Clin Hypertens (Greenwich). 2022. PMID: 36094783 Free PMC article. Clinical Trial.
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, Jeon D, Lee T, Lee JY, Park JS, Lee SH, Kang YA, Lee JK, Kwak N, Ahn JH, Shim TS, Kim SY, Kim S, Kim K, Seok KH, Yoon S, Kim YR, Kim J, Yim D, Hahn S, Cho SN, Yim JJ; MDR-END investigators. Mok J, et al. Among authors: kim sy. Lancet. 2022 Oct 29;400(10362):1522-1530. doi: 10.1016/S0140-6736(22)01883-9. Lancet. 2022. PMID: 36522208 Clinical Trial.
Dual-channel P-type ternary DNTT-graphene barristor.
Lee Y, Kim SM, Kim K, Kim SY, Lee HI, Kwon H, Lee HW, Kim C, Some S, Hwang HJ, Lee BH. Lee Y, et al. Among authors: kim sy. Sci Rep. 2022 Nov 12;12(1):19423. doi: 10.1038/s41598-022-23669-w. Sci Rep. 2022. PMID: 36371420 Free PMC article.
Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment.
Wang Z, Kim SY, Tu W, Kim J, Xu A, Yang YM, Matsuda M, Reolizo L, Tsuchiya T, Billet S, Gangi A, Noureddin M, Falk BA, Kim S, Fan W, Tighiouart M, You S, Lewis MS, Pandol SJ, Di Vizio D, Merchant A, Posadas EM, Bhowmick NA, Lu SC, Seki E. Wang Z, et al. Among authors: kim sy. Cell Metab. 2023 May 9:S1550-4131(23)00140-7. doi: 10.1016/j.cmet.2023.04.013. Online ahead of print. Cell Metab. 2023. PMID: 37172577
11,356 results
You have reached the last available page of results. Please see the User Guide for more information.